InflaRx (IFRX) Operating Income (2018 - 2026)
InflaRx's (IFRX) quarterly Operating Income came in at -$8.4 million in Q1 2026, up 38.31% year-on-year from -$6.1 million in Q1 2025, and down 120.48% quarter-over-quarter from $41.2 million in Q4 2025.
InflaRx (IFRX) Operating Income (2018 - 2026) Analysis & Trends
InflaRx has disclosed Operating Income across 9 years of filings, most recently posting -$8.4 million for Q1 2026.
- Operating Income for Q1 2026 came in at -$8.4 million, up 38.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.1 million (up 870.36% YoY), and the FY2025 annual result was -$56.18, up 0.83% from the prior year.
- Operating Income came in at -$8.4 million for Q1 2026 at InflaRx, down from $41.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $46.2 million in Q4 2024 to a low of -$16.9 million in Q3 2024.
- The 5-year median for Operating Income is -$11.1 million (2025), against an average of -$4.1 million.
- Across the five-year window, Operating Income sank 140083597.94% in 2023 and jumped 422.78% in 2024, its largest moves.
- InflaRx's Operating Income stood at -$7.9 million in 2022, then tumbled by 82.27% to -$14.3 million in 2023, then soared by 422.78% to $46.2 million in 2024, then slipped by 10.83% to $41.2 million in 2025, then plunged by 120.48% to -$8.4 million in 2026.
- The last three Operating Income figures came in at -$8.4 million (Q1 2026), $41.2 million (Q4 2025), and -$11.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -65.83 Mn |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | -8.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.44 Mn |
| Dec 31, 2025 | 41.21 Mn |
| Sep 30, 2025 | -11.08 Mn |
| Jun 30, 2025 | -14.62 Mn |
| Mar 31, 2025 | -13.68 Mn |
| Dec 31, 2024 | 46.21 Mn |
| Sep 30, 2024 | -16.87 Mn |
| Jun 30, 2024 | -16.58 Mn |
| Mar 31, 2024 | -13.57 Mn |
| Dec 31, 2023 | -14.32 Mn |
| Sep 30, 2023 | -12.14 Mn |
| Jun 30, 2023 | -10.73 Mn |
| Mar 31, 2023 | -11.37 |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | 8.67 |
| Jun 30, 2022 | -1.16 Mn |
| Mar 31, 2022 | -16.68 Mn |
| Dec 31, 2021 | -14.87 Mn |
| Sep 30, 2021 | -15.02 Mn |
| Jun 30, 2021 | -16.84 Mn |